Similarly, Smad3—a key downstream effector of TGF-β1 signaling—can be targeted using oligonucleotide inhibitors (e.g., SIS3) or small molecules to block profibrotic signals, as validated in liver fibrosis models (28). This evidence concerns the gene TGFB1 and Hepatic fibrosis.